Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Atara Biotherapeutics stock

Learn how to easily invest in Atara Biotherapeutics stock.

Atara Biotherapeutics Inc is a biotechnology business based in the US. Atara Biotherapeutics shares (ATRA) are listed on the NASDAQ and all prices are listed in US Dollars. Atara Biotherapeutics employs 578 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Atara Biotherapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ATRA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Atara Biotherapeutics stock price (NASDAQ: ATRA)

Use our graph to track the performance of ATRA stocks over time.

Atara Biotherapeutics shares at a glance

Information last updated 2022-01-25.
Latest market close$15.25
52-week range$11.81 - $21.85
50-day moving average $16.48
200-day moving average $15.19
Wall St. target price$33.57
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.62

Buy Atara Biotherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Stocks
$0
0%
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$0
$1 per month
$5
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Public
Stocks, ETFs, Cryptocurrency
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Atara Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atara Biotherapeutics price performance over time

Historical closes compared with the close of $15.25 from 2022-01-26

1 week (2022-01-21) 9.01%
1 month (2021-12-24) N/A
3 months (2021-10-28) -2.49%
6 months (2021-07-28) 15.62%
1 year (2021-01-28) -19.74%
2 years (2020-01-28) 8.93%
3 years (2019-01-28) 34.45
5 years (2017-01-27) 13.38%

Atara Biotherapeutics financials

Revenue TTM $12.8 million
Gross profit TTM $0
Return on assets TTM -48.04%
Return on equity TTM -98.81%
Profit margin 0%
Book value $3.51
Market capitalisation $1.4 billion

TTM: trailing 12 months

Atara Biotherapeutics share dividends

We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months.

Atara Biotherapeutics share price volatility

Over the last 12 months, Atara Biotherapeutics's shares have ranged in value from as little as $11.81 up to $21.85. A popular way to gauge a stock's volatility is its "beta".

ATRA.US volatility(beta: 1.86)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 1.8616. This would suggest that Atara Biotherapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Atara Biotherapeutics overview

Atara Biotherapeutics, Inc. , an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H.

Frequently asked questions

What percentage of Atara Biotherapeutics is owned by insiders or institutions?
Currently 0.489% of Atara Biotherapeutics shares are held by insiders and 105.772% by institutions.
How many people work for Atara Biotherapeutics?
Latest data suggests 578 work at Atara Biotherapeutics.
When does the fiscal year end for Atara Biotherapeutics?
Atara Biotherapeutics's fiscal year ends in December.
Where is Atara Biotherapeutics based?
Atara Biotherapeutics's address is: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
What is Atara Biotherapeutics's ISIN number?
Atara Biotherapeutics's international securities identification number is: US0465131078
What is Atara Biotherapeutics's CUSIP number?
Atara Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 046513107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site